Predictors	predictors	O	O	O	O
of	of	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
during	during	O	O	O	O
angiotensin-converting	angiotensin-converting	O	O	O	O
enzyme	enzyme	O	O	O	O
inhibitor	inhibitor	O	O	O	O
therapy	therapy	O	O	O	O
:	:	O	O	O	O
results	results	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
studies	studies	O	O	O	O
of	of	O	O	O	O
left	left	O	O	OTHERS	I
ventricular	ventricular	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
(SOLVD)BACKGROUND	(solvd)background	O	O	O	O
:	:	O	O	O	O
Although	although	O	O	O	O
angiotensin-converting	angiotensin-converting	O	O	O	O
enzyme	enzyme	O	O	O	O
inhibitor	inhibitor	O	O	O	O
therapy	therapy	O	O	O	O
reduces	reduces	O	O	O	O
mortality	mortality	O	O	O	O
rates	rates	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
(	(	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
it	it	O	O	O	O
may	may	O	O	O	O
also	also	O	O	O	O
cause	cause	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
.	.	O	O	O	O

Little	little	O	O	O	O
information	information	O	O	O	O
is	is	O	O	O	O
available	available	O	O	O	O
to	to	O	O	O	O
predict	predict	O	O	O	O
which	which	O	O	O	O
patients	patients	O	O	O	O
are	are	O	O	O	O
at	at	O	O	O	O
highest	highest	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
this	this	O	O	O	O
complication	complication	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
quantify	quantify	O	O	O	O
specific	specific	O	O	O	O
clinical	clinical	O	O	O	O
predictors	predictors	O	O	O	O
of	of	O	O	O	O
reduction	reduction	O	O	OTHERS	I
in	in	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
who	who	O	O	O	O
are	are	O	O	O	O
prescribed	prescribed	O	O	O	O
angiotensin-converting	angiotensin-converting	O	O	O	O
enzyme	enzyme	O	O	O	O
inhibitor	inhibitor	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

METHOD	method	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
analyzed	analyzed	O	O	O	O
data	data	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
Studies	studies	O	O	O	O
of	of	O	O	O	O
Left	left	O	O	OTHERS	I
Ventricular	ventricular	O	DISEASE	OTHERS	I
Dysfunction	dysfunction	O	DISEASE	OTHERS	I
(	(	O	O	O	O
SOLVD	solvd	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
3379	3379	O	O	O	O
patients	patients	O	O	O	O
randomly	randomly	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
with	with	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
follow-up	follow-up	O	O	O	O
of	of	O	O	O	O
974	974	O	O	O	O
days	days	O	O	O	O
and	and	O	O	O	O
3379	3379	O	O	O	O
patients	patients	O	O	O	O
randomly	randomly	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
placebo	placebo	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
mean	mean	O	O	O	O
follow-up	follow-up	O	O	O	O
of	of	O	O	O	O
967	967	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

Decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
was	was	O	O	O	O
defined	defined	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
rise	rise	O	O	O	O
in	in	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
>	>	O	O	O	O
/=0.5	/=0.5	O	O	O	O
mg/dL	mg/dl	O	O	O	O
(	(	O	O	O	O
44	44	O	O	O	O
micromol/L	micromol/l	O	O	O	O
)	)	O	O	O	O
from	from	O	O	O	O
baseline	baseline	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
used	used	O	O	O	O
time-to-event	time-to-event	O	O	O	O
analysis	analysis	O	O	O	O
to	to	O	O	O	O
identify	identify	O	O	O	O
potential	potential	O	O	O	O
predictors	predictors	O	O	O	O
of	of	O	O	O	O
decrease	decrease	O	O	O	O
in	in	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
including	including	O	O	O	O
age	age	O	O	O	O
,	,	O	O	O	O
baseline	baseline	O	O	O	O
ejection	ejection	O	O	O	O
fraction	fraction	O	O	O	O
,	,	O	O	O	O
baseline	baseline	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
low	low	O	O	O	O
systolic	systolic	O	O	O	O
blood	blood	O	O	O	O
pressure	pressure	O	O	O	O
(	(	O	O	O	O
<	<	O	O	O	O
100	100	O	O	O	O
mm	mm	O	O	OTHERS	I
Hg	hg	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
diabetes	diabetes	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
antiplatelet	antiplatelet	O	O	O	O
,	,	O	O	O	O
diuretic	diuretic	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
beta-blocker	beta-blocker	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Patients	patients	O	O	O	O
randomly	randomly	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
had	had	O	O	O	O
a	a	O	O	O	O
33	33	O	O	O	O
%	%	O	O	O	O
greater	greater	O	O	O	O
likelihood	likelihood	O	O	O	O
of	of	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
than	than	O	O	O	O
controls	controls	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
.003	.003	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

By	by	O	O	O	O
multivariate	multivariate	O	O	O	O
analysis	analysis	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
both	both	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
and	and	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
groups	groups	O	O	O	O
older	older	O	O	O	O
age	age	O	O	O	O
,	,	O	O	O	O
diuretic	diuretic	O	O	OTHERS	I
therapy	therapy	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
diabetes	diabetes	O	DISEASE	OTHERS	I
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
,	,	O	O	O	O
whereas	whereas	O	O	O	O
beta-blocker	beta-blocker	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
higher	higher	O	O	O	O
ejection	ejection	O	O	O	O
fraction	fraction	O	O	O	O
were	were	O	O	O	O
renoprotective	renoprotective	O	O	O	O
.	.	O	O	O	O

Older	older	O	O	O	O
age	age	O	O	O	O
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
greater	greater	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
developing	developing	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
in	in	O	O	O	O
both	both	O	O	O	O
groups	groups	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
significantly	significantly	O	O	O	O
more	more	O	O	O	O
so	so	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
group	group	O	O	O	O
(	(	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
risk	risk	O	O	O	O
ratio	ratio	O	O	O	O
[	[	O	O	O	O
RR	rr	O	O	O	O
]	]	O	O	O	O
1.42	1.42	O	O	O	O
per	per	O	O	O	O
10	10	O	O	O	O
years	years	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
[	[	O	O	O	O
CI	ci	O	O	O	O
]	]	O	O	O	O
1.32	1.32	O	O	O	O
-	-	O	O	O	O
1.52	1.52	O	O	O	O
with	with	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
;	;	O	O	O	O
placebo	placebo	O	O	O	O
:	:	O	O	O	O
RR	rr	O	O	O	O
1.18	1.18	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
1.12	1.12	O	O	O	O
-	-	O	O	O	O
1.25	1.25	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Diuretic	diuretic	O	O	OTHERS	I
therapy	therapy	O	O	O	O
was	was	O	O	O	O
likewise	likewise	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
greater	greater	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
group	group	O	O	O	O
(	(	O	O	O	O
RR	rr	O	O	O	O
1.89	1.89	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
1.70	1.70	O	O	O	O
-	-	O	O	O	O
2.08	2.08	O	O	O	O
)	)	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
(	(	O	O	O	O
RR	rr	O	O	O	O
1.35	1.35	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
1.09	1.09	O	O	O	O
-	-	O	O	O	O
1.66	1.66	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Conversely	conversely	O	O	O	O
,	,	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
had	had	O	O	O	O
a	a	O	O	O	O
relative	relative	O	O	O	O
renoprotective	renoprotective	O	O	O	O
effect	effect	O	O	O	O
(	(	O	O	O	O
RR	rr	O	O	O	O
1.33	1.33	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
1.13	1.13	O	O	O	O
-	-	O	O	O	O
1.53	1.53	O	O	O	O
)	)	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
RR	rr	O	O	O	O
1.96	1.96	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
1.57	1.57	O	O	O	O
-	-	O	O	O	O
2.44	2.44	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
diabetes	diabetes	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
lower	lower	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
renal	renal	O	O	OTHERS	I
impairment	impairment	O	O	OTHERS	I
was	was	O	O	O	O
seen	seen	O	O	O	O
in	in	O	O	O	O
both	both	O	O	O	O
groups	groups	O	O	O	O
with	with	O	O	O	O
beta-blocker	beta-blocker	O	O	O	O
therapy	therapy	O	O	O	O
(	(	O	O	O	O
RR	rr	O	O	O	O
0.70	0.70	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
0.57	0.57	O	O	O	O
-	-	O	O	O	O
0.85	0.85	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
higher	higher	O	O	O	O
baseline	baseline	O	O	O	O
ejection	ejection	O	O	O	O
fraction	fraction	O	O	O	O
(	(	O	O	O	O
RR	rr	O	O	O	O
0.93	0.93	O	O	O	O
per	per	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
increment	increment	O	O	O	O
,	,	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
0.91	0.91	O	O	O	O
-	-	O	O	O	O
0	0	O	O	O	O
.	.	O	O	O	O
96	96	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Enalapril	enalapril	CHEMICALS	O	OTHERS	I
use	use	O	O	O	O
caused	caused	O	O	O	O
a	a	O	O	O	O
33	33	O	O	O	O
%	%	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
decreased	decreased	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Diuretic	diuretic	O	O	OTHERS	I
use	use	O	O	O	O
and	and	O	O	O	O
advanced	advanced	O	O	O	O
age	age	O	O	O	O
increased	increased	O	O	O	O
this	this	O	O	O	O
risk	risk	O	O	O	O
.	.	O	O	O	O

Diabetes	diabetes	O	DISEASE	OTHERS	I
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
renal	renal	O	O	OTHERS	I
impairment	impairment	O	O	OTHERS	I
in	in	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
this	this	O	O	O	O
risk	risk	O	O	O	O
was	was	O	O	O	O
reduced	reduced	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
group	group	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
.	.	O	O	O	O

beta-Blocker	beta-blocker	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
higher	higher	O	O	O	O
ejection	ejection	O	O	O	O
fraction	fraction	O	O	O	O
were	were	O	O	O	O
renoprotective	renoprotective	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
regardless	regardless	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

